Clinical Trials Logo

Exocrine Pancreatic Cancer clinical trials

View clinical trials related to Exocrine Pancreatic Cancer.

Filter by:
  • None
  • Page 1

NCT ID: NCT04930991 Recruiting - Clinical trials for Exocrine Pancreatic Cancer

High Dose Omeprazole in Patients With Pancreatic Cancer

OU202005AJ
Start date: September 7, 2021
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to test the safety of high dose omeprazole and see what effects that it has on patients with exocrine pancreatic cancer.

NCT ID: NCT04011982 Recruiting - Clinical trials for Exocrine Pancreatic Cancer

PATAKESS Protocol : Clinical and Biological Analysis of Exocrine Pancreatic Tumors

PATAKESS
Start date: September 1, 2020
Phase:
Study type: Observational

PATAKESS is a monocentric non interventional cohort study (prospective (alive patients) and retrospective (dead patients with biological material from surgery and/or biopsies already collected)). PATAKESS consists of clinical and biological analyses of exocrine pancreatic tumors. Data are derived from tumor samples taken for routine health care purposes in patients managed at Centre Léon Bérard (Lyon-France) since January 2010. The main objective is to determine correlation between biological and clinical characterizations of patients suffering from exocrine pancreatic tumor.

NCT ID: NCT03485209 Recruiting - Clinical trials for Carcinoma, Non-Small-Cell Lung

Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

innovaTV 207
Start date: June 25, 2018
Phase: Phase 2
Study type: Interventional

This trial will study tisotumab vedotin to find out whether it is an effective treatment for certain solid tumors and what side effects (unwanted effects) may occur. There are seven parts to this study. - In Part A, the treatment will be given to participants every 3 weeks (3-week cycles). - In Part B, participants will receive tisotumab vedotin on Days 1, 8, and 15 every 4-week cycle. - In Part C, participants will receive tisotumab vedotin on Days 1 and 15 of every 4-week cycle. - In Part D, participants will be given treatment on Day 1 of every 3-week cycle. Participants in Part D will get tisotumab vedotin with either: - Pembrolizumab or, - Pembrolizumab and carboplatin, or - Pembrolizumab and cisplatin - In Part E, participants will receive tisotumab vedotin on Days 1 and 15 of every 4-week cycle. - In Part F, participants will receive tisotumab vedotin on Days 1, 15, and 29 of every 6-week cycle. Participants in Part F will get tisotumab vedotin with pembrolizumab. - In Part G, participants will receive tisotumab vedotin on Days 1, 15, and 29 of every 6-week cycle. Participants in Part G will get tisotumab vedotin with pembrolizumab and carboplatin.

NCT ID: NCT01020006 Completed - Pancreatic Cancer Clinical Trials

Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine

Start date: November 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of selected dose 1.2mg/kg BID dosage administered subcutaneously (SC) administered PCI-27483 to metastatic or locally advanced pancreatic cancer patients receiving concurrent therapy with intravenously administered gemcitabine for 12 weeks.